Nano-X Imaging’s HealthCCSng AI solution, developed by Nanox.AI, revealed previously undetected cardiovascular risk in 58% of patients during a study conducted at Israel’s Beilinson Hospital. This innovative technology automatically analyzed coronary artery calcium (CAC) levels from routine chest CT scans, aiding in the early identification and prevention of cardiac events. HealthCCSng’s ability to detect hidden risks from routine scans promises to revolutionize preventive cardiac care and reduce the global burden of cardiovascular disease. Nanox.AI’s solutions, including HealthOST and HealthFLD, leverage AI to identify early signs of various diseases through routine medical CT imaging.
Nano-X Imaging, an innovative medical imaging technology company, has announced a groundbreaking clinical study conducted at Beilinson Hospital in Israel, utilizing Nanox.AI’s HealthCCSng AI-powered solution. The study aimed to assess the impact of AI-based coronary artery calcium (CAC) measurements on routine chest CT scans, revealing that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium, a strong predictor of future cardiac events. This study, sponsored by Nanox.AI, was carried out by Beilinson Hospital, a prestigious multidisciplinary medical institution in Israel.
HealthCCSng is an FDA-cleared and CE-marked tool developed by Nanox.AI, specifically designed for cardiac health assessment. It harnesses medical imaging data from routine chest CT scans to automatically quantify and analyze CAC categories. CAC is a robust indicator of future cardiac events, with patients in the highest category being over 20 times more likely to experience a cardiac event.
Professor Ran Kornowski, Director of the Cardiology Center at Beilinson Hospital, leading the study along with Professor Ashraf Hamdan, Director of the Cardiovascular Imaging unit, highlighted the potential of Nanox’s AI technology to identify individuals with high CAC levels from routine CT scans who were unaware of their cardiac risk. This early risk identification and prevention through AI are seen as promising steps in reducing cardiac events.
The study utilized Nanox.AI’s HealthCCSng software to assess Coronary Artery Calcification (CAC) levels from non-gated, non-contrast chest CT scans. Radiologists qualitatively evaluated the software’s categorizations, which included low (CAC 0-99), moderate (CAC 100-399), and severe (CAC > 400) levels, with exclusions for specific medical histories or artifacts.
Prof. Ashraf Hamdan, Head of Cardiovascular Imaging at Beilinson Hospital and chief investigator, praised the integration of HealthCCSng within their hospital, emphasizing its ability to detect hidden cardiovascular risks from routine CT scans and guide patients to appropriate care.
Among the 326 eligible patients participating in the study from January to July 2023, 31% exhibited severe CAC, 27% had moderate CAC, and 42% showed low CAC levels. Patients with severe CAC were referred to specialized preventive cardiology clinics, while those with low and moderate CAC were directed to primary care physicians for further assessment.
Dr. Orit Wimpfheimer, Chief Medical Officer of Nanox.AI, stressed the importance of HealthCCSng in detecting hidden cardiovascular risks early, given the global prominence of cardiovascular disease as a leading cause of mortality.
Traditionally, CAC scoring required cardiac-gated scans, incurring additional costs and radiation exposure not covered by insurance. HealthCCSng supports clinicians in diagnosing previously undetected cardiovascular disease, enabling early intervention and tailored care pathways to prevent or mitigate future incidents.
Nanox.AI’s solutions aim to address prevalent chronic and acute diseases on a global scale, helping clinicians uncover valuable clinical insights from medical imaging. Beyond HealthCCSng, Nanox.AI’s portfolio includes FDA-cleared imaging solutions in bone health (HealthOST) and fatty liver disease (HealthFLD), using routine medical CT imaging to identify early signs of diseases, ultimately preventing life-changing health events.
